oral D1 modulator

Ph. I candidate for neurological disorders

opt. against DDI w/ hepatocyte Cl assay

J. Med. Chem.

Eli Lilly and Company

oral D1 modulator - Eli Lilly and Company

Context. LY3154885 (Eli Lilly and Company) is an oral D1 modulator. Lilly recently completed several clinical trials with LY3154207 (mevidalen), the first D1 positive allosteric modulator (D1PAM) with published…

get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: